Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, Okajima Y, Kurotobi S, Hirai K, Soga T, Ishiguchi Y, Okuma Y, Takada N, Yanai M, Sato J, Nakayashiro M, Ayusawa M, Yamamoto E, Nomura Y, Hashimura Y, Ouchi K, Masuda H, Takatsuki S, Hirono K, Ariga T, Higaki T, Otsuki A, Terauchi M, Aoyagi R, Sato T, Fujii Y, Fujiwara T, Hanaoka H, Hata A; KAICA trial Investigators. Hamada H, et al. Among authors: aoyagi r. Lancet. 2019 Mar 16;393(10176):1128-1137. doi: 10.1016/S0140-6736(18)32003-8. Epub 2019 Mar 7. Lancet. 2019. PMID: 30853151 Clinical Trial.
Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial).
Aoyagi R, Hamada H, Sato Y, Suzuki H, Onouchi Y, Ebata R, Nagashima K, Terauchi M, Terai M, Hanaoka H, Hata A; KAICA Trial Investigators. Aoyagi R, et al. BMJ Open. 2015 Dec 1;5(12):e009562. doi: 10.1136/bmjopen-2015-009562. BMJ Open. 2015. PMID: 26628527 Free PMC article. Clinical Trial.
Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial.
Misawa S, Sato Y, Katayama K, Nagashima K, Aoyagi R, Sekiguchi Y, Sobue G, Koike H, Yabe I, Sasaki H, Watanabe O, Takashima H, Nishizawa M, Kawachi I, Kusunoki S, Mitsui Y, Kikuchi S, Nakashima I, Ikeda S, Kohara N, Kanda T, Kira J, Hanaoka H, Kuwabara S; Japanese POEMS Syndrome for Thalidomide (J-POST) Trial Study Group. Misawa S, et al. Among authors: aoyagi r. Lancet Neurol. 2016 Oct;15(11):1129-37. doi: 10.1016/S1474-4422(16)30157-0. Epub 2016 Aug 3. Lancet Neurol. 2016. PMID: 27496680 Clinical Trial.
Quantification of Goldmann Visual Fields During Resolution of Traumatic Optic Neuropathy.
Tachibana M, Kanno J, Hashimoto M, Hosokawa Y, Sawada M, Nishiyama-Ota Y, Konno S, Aoyagi R, Ishikawa S, Makita J, Ikezono T, Shinoda K. Tachibana M, et al. Among authors: aoyagi r. Case Rep Ophthalmol Med. 2024 Nov 16;2024:5560696. doi: 10.1155/2024/5560696. eCollection 2024. Case Rep Ophthalmol Med. 2024. PMID: 39583778 Free PMC article.
APEX1 Polymorphisms Affect Acute Myeloid Leukemia Risk, and Its Expression Is Involved in Cell Proliferation and Differentiation.
Gotoh N, Oda T, Kitamura Y, Shiraishi N, Aoyagi R, Omori A, Yanagisawa K, Iida M, Itoi Y, Negishi H, Matsumura I, Kasamatsu T, Miyauchi E, Sasaki N, Takada S, Yokohama A, Handa H, Murakami H, Saitoh T. Gotoh N, et al. Among authors: aoyagi r. Int J Lab Hematol. 2024 Nov 13. doi: 10.1111/ijlh.14401. Online ahead of print. Int J Lab Hematol. 2024. PMID: 39536468
Validated UPLC-MS/MS method for quantification of melatonin receptor agonists and dual orexin receptor antagonists in human plasma and breast milk: Application to quantify suvorexant and lemborexant in clinical samples.
Ishikawa H, Furugen A, Nishimura A, Umazume T, Ishikawa S, Aoyagi R, Narumi K, Okamoto K, Takekuma Y, Sugawara M, Kobayashi M. Ishikawa H, et al. Among authors: aoyagi r. J Pharm Biomed Anal. 2024 Dec 15;251:116432. doi: 10.1016/j.jpba.2024.116432. Epub 2024 Aug 20. J Pharm Biomed Anal. 2024. PMID: 39180895
71 results